Recorded Webinar from May 9, 2023
In this webinar, you will learn:
Polyclonal antibodies (pAbs) are well known for their robustness and epitope diversity, which makes them well suited for use in diagnostics or other assays. However, they suffer from batch-to-batch variability, or complete loss of supply when the host animal dies. Using polyclonal reagents risks costly revalidation efforts for every batch, and the eventual need to start R&D efforts from scratch when supply runs out. A well-selected cocktail of monoclonal antibodies (mAbs) can recapitulate the binding activity of a pAb. But R&D efforts to generate new mAbs that work as well as an established pAb often disappoint.
Subscribe to our Newsletter
Get all the latest updates, and learn about our advancements in antibody production.
Subscribe now
Immunoassays that rely on monoclonal antibodies (mAbs) derived from hybridomas are also prone to supply chain risk. Hybridomas often drift, die, or produce unwanted additional chains eventually leading to immunoassays with changed behaviors.
By producing recombinant monoclonal antibodies (rAbs), IVD manufacturers can ensure a constant and reliable supply of critical reagents. So the question is, how do we convert a pAb to a cocktail of recombinant mAbs? Or how can a mAb be recovered after the hybridoma has already been lost?
In this webinar, we present a single integrated workflow for antibody sequencing and recombinant expression of mAbs. We will present a case study of a successful mAb-to-rAb conversion, describe the methodology in detail, and explain how it can be used to efficiently convert a catalog of mAb or pAb reagents into recombinant antibodies.
Richard Park, BSc
evitria AG
Global Head, Client Relations & Business Development
Richard leads the Client Relations and Business Development team at evitria AG and joins the conversation with a background in diagnostics and assay development in addition to supporting therapeutic research teams. Richard focuses his efforts on support clients navigate the vast number of options available when exploring or further developing immunoassays and therapies.
Anthony Stajduhar, BSc
Rapid Novor
Director of Business Development
Anthony works on the cutting edge of protein analysis technology, and has given dozens of talks to antibody researchers around the world. As Rapid Novor’s Global Director of Business Development, Anthony is dedicated to solving challenging technical problems in the biomedical field, while enriching the lives of humans around the world.
Recombinant antibody expression service